The effect of Intense Pulsed Light therapy on eyelid bacterial load in contact lens discomfort.

Cont Lens Anterior EyeJul 19, 2026 (epub)
Clinical ResearchOphthalmology

Srikanth Dumpati, Fatima Iqbal, Ajay Kumar Vijay et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial assessed the impact of Intense Pulsed Light (IPL) therapy on eyelid microbiota in symptomatic contact lens wearers. Eighteen participants completed the study, revealing a significant reduction in bacterial load (CFU/swab) in the IPL group from day 0 to day 42, particularly for total gram-positive cocci and coagulase-negative staphylococci (p < 0.001).

Key findings

  • IPL therapy reduced total gram-positive cocci from 174.0 ± 11.5 to 122.0 ± 8.4 CFU/swab by day 42 (p < 0.001).
  • Total gram-positive rods decreased from 174.0 ± 8.2 to 126.0 ± 8.2 CFU/swab by day 42 (p < 0.001).
  • Coagulase-negative staphylococci counts dropped from 174.0 ± 12.2 to 122.0 ± 10.0 CFU/swab by day 42 (p < 0.001).
  • By day 90, bacterial counts partially rebounded towards baseline levels.

Why it matters

Understanding the effects of IPL therapy on eyelid microbiota can inform treatment strategies for contact lens discomfort, potentially improving patient outcomes and comfort in symptomatic wearers.

Source

PubMed · PMID 42472534

Published in Cont Lens Anterior Eye. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.